Purple Biotech Ltd. (PPBT) AI Stock Analysis
PPBT AI stock analysis summary
AI ResearchPurple Biotech Ltd. is a clinical-stage biopharmaceutical company developing oncology drug candidates CM24 and NT219. Over the trailing twelve months ended June 30, 2026, the company generated $0 in revenue and posted an EPS of -$47.64. As of October 16, 2026, the stock closed at $1.14 with a market capitalization of $1.9M.
- Market cap
- $1.9M
- Revenue (TTM)
- $0
- P/E
- —
- 1Y return
- -81.6% S&P 500 16.8%
- Avg. target
- $17.00 1391.2% vs last close
Bull case
- The single analyst covering the stock has a mean price target of $17.00, which is 1391.2% above the last closing price of $1.14.
- The company maintains a net cash position of $6.0M, holding $6.1M in cash and short-term investments against $134,000 in total debt as of June 30, 2026.
- Short-term liquidity remains supported by a current ratio of 3.70 and a debt-to-equity ratio of 0.01 as of June 30, 2026.
Bear case
- The company generated $0 in revenue over the trailing twelve months and recorded a five-year revenue CAGR of -27.8% from FY2018 to FY2023.
- PPBT shares have dropped 81.6% over the trailing one-year period and -99.9% over five years, trailing the S&P 500 return of 16.8% over the past year.
- Shareholders have seen substantial equity dilution, reflected by an 1138.4% increase in the share count over five years.
What Purple Biotech does
Purple Biotech Ltd. is a clinical-stage biopharmaceutical company based in Rehovot, Israel, focused on advancing therapies to overcome tumor immune evasion and enhance treatment options for cancer patients. Its clinical pipeline includes CM24, a monoclonal antibody blocking CEACAM1 being evaluated in Phase 1b/2 trials alongside anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. It is also developing NT219, a small molecule targeting IRS1/2 and STAT, in Phase 1/2 trials for recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. Founded as Kitov Pharma Ltd., the company rebranded in December 2020.
Growth and profitability
Purple Biotech reported annual revenue of $1.0M in FY2019 and FY2020, followed by -$320,000 in FY2021, -$910,000 in FY2022, and $195,804 in FY2023. Over the five-year period from FY2018 to FY2023, revenue had a compound annual growth rate of -27.8%. Annual net losses were -$5.8M in FY2019, -$28.2M in FY2020, -$18.4M in FY2021, -$21.7M in FY2022, and -$19.9M in FY2023. Diluted EPS was -$76.42 in FY2021, -$105.07 in FY2022, and -$190.98 in FY2023. Research and development expenses were $17.0M in FY2023, compared to $2.3M in FY2019. For the trailing twelve months ended June 30, 2026, revenue was $0, operating margin was 0.0%, and EPS was -$47.64.
Balance sheet and cash flow
As of June 30, 2026, Purple Biotech held $6.1M in cash and short-term investments, with total debt of $134,000, resulting in net cash of $6.0M. Total assets were $14.2M, and shareholders' equity was $12.3M. The company reported a current ratio of 3.70 and a debt-to-equity ratio of 0.01. Operating cash flow in FY2023 was -$19.9M, matching free cash flow of -$19.9M. In FY2025, capital expenditures were $3,025, while the five-year change in share count was 1138.4%.
Valuation and performance
At the last close of $1.14 on October 16, 2026, Purple Biotech had a market capitalization of $1.9M and an enterprise value of $4.8M. The company trades at a price-to-sales ratio of 58.1x and an EV-to-revenue ratio of 33.1x, compared to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 0.2x. Over the past year, the stock returned -81.6%, while the S&P 500 (SPY) returned 16.8%. Over five years, the stock returned -99.9% compared to 83.0% for the S&P 500.
What analysts expect
Purple Biotech has 1 Strong Buy rating, 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $17.00, representing a 1391.2% premium over the October 16, 2026 closing price of $1.14. For the fiscal year ending December 31, 2026, the EPS estimate is -$5.73 on projected revenue of $0. For the following fiscal year, 1 analyst estimates EPS of -$1.01 on revenue of $0. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 13, 2026.
Key risks and what to watch
- Ongoing cash burn was -$19.9M in free cash flow during FY2023 against $6.1M in cash and short-term investments as of June 30, 2026.
- Trailing twelve months return on equity was -111.1%, reflecting persistent net losses.
- Consensus estimates forecast continued losses with an EPS of -$5.73 for FY2026 and -$1.01 for FY2027.
- Trading at $1.14, the stock sits just above its 52-week low of $1.13 and is 65.5% below its 200-day average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this PPBT AI stock analysis
This page is an AI-written research summary of Purple Biotech Ltd. (PPBT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: PPBT income statement, PPBT balance sheet, PPBT key metrics, PPBT analyst forecast, PPBT chart. See the PPBT stock overview for the latest quote and news.
PPBT AI stock analysis FAQ
What does Purple Biotech do?
Purple Biotech Ltd. is a clinical-stage biopharmaceutical company developing cancer treatments. Its primary oncology pipeline includes CM24 in Phase 1b/2 trials and NT219 in Phase 1/2 trials.
Does Purple Biotech pay a dividend?
No, Purple Biotech does not pay a dividend. The company is in the clinical stage and generated $0 in revenue over the trailing twelve months ending June 30, 2026.
What is Purple Biotech's cash and debt position?
As of June 30, 2026, the company had $6.1M in cash and short-term investments and $134,000 in total debt, giving it a net cash balance of $6.0M.
What are analysts forecasting for Purple Biotech?
As of October 16, 2026, 1 analyst rates the stock a Strong Buy with a price target of $17.00. Estimates project an EPS of -$5.73 for FY2026 and -$1.01 for FY2027, with $0 in projected revenue for both years.